SCHEMBL1036161

SCHEMBL1036161

C[C@H](N)C(=O)N[C@@H](C)C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.50
PAX8 Q06710 1/20 0.50
DPP8 Q6V1X1 2/20 0.39
DPP7 Q9UHL4 2/20 0.39
SLC15A1 P46059 1/20 0.38
CTRB1 P17538 5/20 0.37
FAP Q12884 1/20 0.33
DPP9 Q86TI2 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32
CTSS P25774 1/20 0.32
XIAP P98170 1/20 0.31
BIRC2 Q13490 1/20 0.31
NOD1 Q9Y239 1/20 0.30
IDO1 P14902 1/20 0.30
GABRP O00591 1/20 0.30
GABRD O14764 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRB1 P18505 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14151828 1.00 DPP4 (0.50) DPP4PAX8DPP8DPP7SLC15A1
SCHEMBL10073576 0.92 PAX8 (0.45) DPP4PAX8DPP8DPP7SLC15A1
SCHEMBL12251245 0.92 PAX8 (0.45) DPP4PAX8DPP8DPP7SLC15A1
SCHEMBL10072974 0.92 PAX8 (0.45) DPP4PAX8DPP8DPP7SLC15A1
SCHEMBL14590394 0.85 PAX8 (0.39) DPP4PAX8CTRB1CTSS
SCHEMBL23169746 0.82 DPP4 (0.53) DPP4PAX8DPP8DPP7FAP
SCHEMBL12285003 0.82 DPP4 (0.53) DPP4PAX8DPP8DPP7FAP
SCHEMBL1034777 0.82 DPP4 (0.53) DPP4PAX8DPP8DPP7FAP
SCHEMBL17209389 0.80 CTSC (0.41) DPP4PAX8DPP8DPP7FAP
SCHEMBL12428127 0.80 CTSC (0.41) DPP4PAX8DPP8DPP7FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277884-B1 ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2017-08-23 EP disclosed
US-9115165-B2 Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-08-25 US disclosed
US-20110224161-A1 TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2011-09-15 US disclosed
EP-2277884-A1 ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224161-A1 TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF DHPS, TBCA, ANTXR2 DPP4 3343/4885PAX8 4236/4885DPP8 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.